Cogan syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1467H16.3
Who is this for?
Show terms as
19Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Cogan syndrome is a rare, chronic inflammatory disorder characterized by interstitial keratitis (inflammation of the cornea) and vestibuloauditory dysfunction, which includes sensorineural hearing loss, tinnitus, and vertigo resembling Ménière disease. The condition is classified as a systemic vasculitis and can affect multiple organ systems beyond the eyes and ears. It was first described by David Cogan in 1945. The disease is thought to have an autoimmune etiology, though the exact cause remains unknown. It is not considered a hereditary condition. Cogan syndrome primarily affects young adults, with a typical onset between the ages of 20 and 30, though it can occur at any age. In addition to ocular and audiovestibular symptoms, patients may experience systemic vasculitis affecting large, medium, and small blood vessels. This can lead to aortitis (inflammation of the aorta), aortic insufficiency, and involvement of other organs including the musculoskeletal system (arthralgia, myalgia), gastrointestinal tract, kidneys, and central nervous system. Constitutional symptoms such as fever, fatigue, and weight loss are common. Approximately 10-15% of patients may develop life-threatening cardiovascular complications, particularly aortic valve disease requiring surgical intervention. Treatment of Cogan syndrome typically involves systemic corticosteroids as first-line therapy to control inflammation and preserve hearing and vision. Topical corticosteroid eye drops are used for ocular inflammation. In patients who are refractory to corticosteroids or who require long-term immunosuppression, steroid-sparing agents such as methotrexate, azathioprine, cyclophosphamide, mycophenolate mofetil, or biologic agents (e.g., TNF-alpha inhibitors, rituximab) may be employed. Early and aggressive treatment is critical, as delayed therapy can result in permanent sensorineural hearing loss, which occurs in a significant proportion of patients. Cochlear implantation has been used successfully in patients with profound bilateral hearing loss. Cardiovascular complications may require surgical repair, including aortic valve replacement.

Clinical phenotype terms— hover any for plain English:

Abnormal vestibular functionHP:0001751ThrombocytosisHP:0001894Inflammatory abnormality of the eyeHP:0100533Large vessel vasculitisHP:0005310ScleritisHP:0100532EpiscleritisHP:0100534
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Cogan syndrome.

View clinical trials →

No actively recruiting trials found for Cogan syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Cogan syndrome community →

Specialists

19 foundView all specialists →
AM
Alberto Benussi, MD
Trieste, Trieste
Specialist

Rare Disease Specialist

PI on 5 active trials
NL
Nicole Lifson
BOSTON, MA
Specialist
1 Cogan syndrome publication
VR
Viren Rana
LONG BEACH, CA
Specialist
1 Cogan syndrome publication
LM
Lewena Maher
RIVERSIDE, RI
Specialist
1 Cogan syndrome publication
LS
Lory Snady-McCoy
PROVIDENCE, RI
Specialist
1 Cogan syndrome publication
AM
Alejandro R Marrero-Gonzalez
Specialist
1 Cogan syndrome publication
HR
Habib G Rizk
CHARLESTON, SC
Specialist
1 Cogan syndrome publication
YC
Yan Chen
Specialist
1 Cogan syndrome publication
AT
Andrew Takla
ROCHESTER, NY
Specialist
1 Cogan syndrome publication
FE
Fahad Eid
ROCHESTER, NY
Specialist
1 Cogan syndrome publication
ME
Mohamed Magdi Eid
Specialist
1 Cogan syndrome publication
SJ
Seth S Jeong
SYRACUSE, NY
Specialist
1 Cogan syndrome publication
JH
Jiarui Hu
Specialist
1 Cogan syndrome publication
DW
Dongze Wu
Specialist
1 Cogan syndrome publication
CW
Celine Ward
CHARLESTON, SC
Specialist
1 Cogan syndrome publication
JZ
Jing Zhu
Specialist
1 Cogan syndrome publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Cogan syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Cogan syndromeForum →

No community posts yet. Be the first to share your experience with Cogan syndrome.

Start the conversation →

Latest news about Cogan syndrome

No recent news articles for Cogan syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Cogan syndrome

What is Cogan syndrome?

Cogan syndrome is a rare, chronic inflammatory disorder characterized by interstitial keratitis (inflammation of the cornea) and vestibuloauditory dysfunction, which includes sensorineural hearing loss, tinnitus, and vertigo resembling Ménière disease. The condition is classified as a systemic vasculitis and can affect multiple organ systems beyond the eyes and ears. It was first described by David Cogan in 1945. The disease is thought to have an autoimmune etiology, though the exact cause remains unknown. It is not considered a hereditary condition. Cogan syndrome primarily affects young adu

How is Cogan syndrome inherited?

Cogan syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Cogan syndrome typically begin?

Typical onset of Cogan syndrome is adult. Age of onset can vary across affected individuals.

Which specialists treat Cogan syndrome?

19 specialists and care centers treating Cogan syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.